The NEU² portfolio encompasses early stage hit discovery through to mature Phase II clinical programs. In each case, projects are invited to make use of the many existing NEU² competencies, from biomarker discovery and implementation to clinical trial design based on innovative imaging endpoints. Hands-on access to the comprehensive know-how and technologies necessary to deliver individual project content is available through the NEU² platforms and consortium members are intimately involved in platform operation and defining their future development as scientific techniques in drug discovery evolve.
NEU²´s core focus is to:
- Connect academic, biotech based and pharmaceutical expertise in the drug development process with the goal to efficiently generate new therapies to tackle multiple sclerosis (MS),
- Identify and test new paradigms underlying neurological diseases using novel molecular entities that have the potential to become superior drugs,
- Make funds available for pre-clinical research and clinical trials of potential MS drugs,
- Expedite the repurposing of existing drugs to treat MS